WEHI PhD Completion Seminar hosted by Associate Professor Nawaf Yassi

Dr Sarah Holper MBBS(Hons) FRACP

PhD Student – Genetics and Gene Regulation division, WEHI

Consultant Neurologist – The Royal Melbourne Hospital | Melbourne Brain Centre, The Australian National CJD Registry | The Florey

Untangling Neuroinflammation’s Role in Alzheimer’s Disease Development (UNRAVEL)

RMH Ewing Theatre

Join via TEAMS

Including Q&A session

My PhD examined plasma biomarkers of tau dysregulation, neuroinflammation, and neurodegeneration in Alzheimer’s disease, evaluating their relationships with cognitive and functional outcomes to enhance diagnostic and prognostic precision. To achieve this, as Principal Investigator I designed and conducted The SAMe Study, a world-first phase II, multi-centre, randomised, double-blind, placebo-controlled trial of S-adenosyl methionine (SAMe) as a potential tau-modifying therapy. Alongside assessing SAMe’s therapeutic effects, I analysed real-world trial biomarker data to determine what these measures revealed about patient function and clinical outcomes, including cognitive performance. Collectively, this work aims to advance the development of accessible, clinically useful plasma biomarkers for Alzheimer’s disease.

All welcome!